Short answer
ASP Isotopes Inc. (ASPI) filed an 8-K current report with the SEC on July 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Press release furnished under Item 7.01 Regulation FD.
ASP Isotopes Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Press release furnished under Item 7.01 Regulation FD
- Forward-looking statements subject to Private Securities Litigation Reform Act safe-harbor protections
Item EX-99.1 · Exhibit EX-99.1
- QLE, ASPI’s wholly owned subsidiary, signed a research agreement with TEES to advance high-purity uranium hexafluoride production
- Research targets U₃O₈-to-UF₆ conversion efficiency, process modeling, scale-up, cost reduction, and commercialization readiness
- Strategic importance: domestic uranium conversion is a critical supply-chain bottleneck, with one operating commercial U.S. conversion facility
- Near-term financial impact appears limited; agreement is development-stage research rather than a disclosed revenue or financing transaction
- Execution risks include funding needs, regulatory approvals, third-party dependence, commercialization, and construction of enrichment facilities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ASP Isotopes Inc. 8-K filings
Get the next ASPI 8-K as it lands
Follow ASPI for push alerts, or ask the research agent what this filing means.